Roche Says Divarasib Cut Lung Cancer Death Risk 44% in Phase III Trial
Roche said its experimental drug divarasib reduced the risk of death by 44% versus existing treatments in a Phase III study of previously treated patients with KRAS G12C-mutated non-small cell lung cancer.